Isabelle Ollivier‐Hourmand
A5052852450- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Colorectal Cancer Treatments and Studies
- Liver Diseases and Immunity
- Hepatitis Viruses Studies and Epidemiology
- Lung Cancer Treatments and Mutations
- Hepatitis B Virus Studies
- Drug-Induced Hepatotoxicity and Protection
- Organ Transplantation Techniques and Outcomes
- Cancer, Lipids, and Metabolism
- Infective Endocarditis Diagnosis and Management
- Renal Transplantation Outcomes and Treatments
- Telomeres, Telomerase, and Senescence
- Cancer Treatment and Pharmacology
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Complement system in diseases
- Cytomegalovirus and herpesvirus research
- Cancer Immunotherapy and Biomarkers
- Abdominal vascular conditions and treatments
- Folate and B Vitamins Research
- Pericarditis and Cardiac Tamponade
- Cholangiocarcinoma and Gallbladder Cancer Studies
Université de Caen Normandie
2015-2025
Centre Hospitalier Universitaire de Caen
2015-2025
Inserm
2023
Normandie Université
2021
Hôpital Saint-Antoine
2020
Sorbonne Université
2020
Centre Hospitalier Universitaire d'Angers
2015-2018
Hôpital Européen Georges-Pompidou
2018
Assistance Publique – Hôpitaux de Paris
2018
Ospedali Riuniti di Ancona
2009
Patients with primary biliary cholangitis who have an inadequate response to therapy ursodeoxycholic acid are at high risk for disease progression. Fibrates, which agonists of peroxisome proliferator-activated receptors, in combination acid, shown potential benefit patients this condition.In 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 100 had according the Paris 2 criteria receive bezafibrate a daily dose 400 mg (50 patients), or placebo addition continued...
There is debate over the effects of long-term oral fluoroquinolone therapy in patients with advanced cirrhosis. We performed a randomized controlled trial to evaluate treatment norfloxacin on survival double-blind 291 Child-Pugh class C cirrhosis who had not received recent therapy. The study was at 18 clinical sites France from April 2010 through November 2014. Patients were randomly assigned groups given 400 mg (n = 144) or placebo 147) once daily for 6 months. evaluated monthly first...
Background and Aims Data about the prognosis of salvage transjugular intrahepatic portosystemic shunt (TIPS) using covered stents for refractory variceal bleeding caused by portal hypertension are scarce. We aimed to assess survival identify predictors mortality in these patients. Approach Results One hundred sixty‐four patients with cirrhosis from five centers treated TIPS between 2007 2017 were retrospectively divided into a derivation cohort (83 patients) validation (81 patients)....
Background and Aims: Since the introduction of SARS-CoV-2 vaccines, several cases vaccine-induced immune thrombocytopenia thrombosis (VITT) have been described, especially cerebral vein thrombosis. We aimed to retrospectively collect all new acute onset first or recurrent splanchnic (SVT) following a recent vaccination within Vascular Liver Disease Group network. Approach Results: New SVT were identified from April 2021 2022; follow-up was completed on December 31, 2022. Criteria define VITT...
412 Background: Skin toxicity is a known adverse effect of multikinase inhibitors, and was shown to be predictor OS in patients (pts) with HCC treated sorafenib (Reig M, 2014). In the RESORCE trial, regorafenib improved versus placebo pts progressing on (HR 0.62, 95% CI 0.50, 0.78; Bruix J, 2017). This retrospective analysis explored whether HFSR associated RESORCE. Methods: Pts who were randomized 160 mg/day during first 3 weeks each 4-week cycle divided into subgroups based or not they had...
A total of 2%-10% patients with vascular liver disease (VLD) have paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab reduces complement-mediated haemolytic activity in PNH. This study was aimed at assessing the impact eculizumab on VLD outcome. Retrospective cohort PNH patients, Valdig registry, who had diagnosed between 1997 and 2019 is considered. exposure interest. Studied outcomes were death, venous thrombosis, bleeding, arterial ischemic event, infection, liver-related complications....
Background and Aim: Germline mutations of telomere-related genes (TRG) induce multiorgan dysfunction, liver-specific manifestations have not been clearly outlined. We aimed to describe TRG mutations-associated liver diseases. Approach Results: Retrospective multicenter analysis disease (transaminases > 30 IU/L and/or abnormal imaging) in patients with mutations. Main measurements were characteristics, outcomes, risk factors a cohort. The prevalence was compared community-based control...
We aimed to assess the performance of a new strip (Periscreen) for rapid diagnosis spontaneous bacterial peritonitis (SBP).Ascitic fluid (AF) cirrhotic patients hospitalized between March 2014 and August 2015 was independently tested by two readers using strip, which has four colorimetric graduations (negative, trace, small, large). SBP diagnosed on neutrophils in ascites>250/mm3. Ascites not related portal hypertension were excluded.Overall, 649 from 21 French centers included 1,402 AF (803...
In patients with noncirrhotic chronic extrahepatic portal vein obstruction (EHPVO), data on the morbimortality of abdominal surgery are scarce.